Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion 2 – Translational research

2381 - Oral Intestinal Alkaline Phosphatase Improves Efficacy of 5-FU in a Colorectal Cancer Mouse Model


30 Sep 2019


Poster Discussion 2 – Translational research


Christian Furlan Freguia


Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268


C. Furlan Freguia, M. Kaleko

Author affiliations

  • ., Synthetic Biologics, 20850 - Rockville/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2381


Intestinal alkaline phosphatase (IAP) is an endogenous intestinal enzyme that promotes gastrointestinal (GI) homeostasis by detoxifying inflammatory mediators, tightening the gut barrier and promoting a healthy microbiome. In previous reports, oral delivery of IAP ameliorated colitis in animals and in a human pilot study. The commonly used chemotherapy, 5-Fluorouracil (5-FU), can cause severe GI damage potentially resulting in dose limiting toxicities. Given the recent implication of the gut microbiome in modulating the anti-cancer response and the role of IAP in mitigating GI toxicity, we sought to evaluate the role of IAP in ameliorating 5-FU related GI side effects and to assess the impact of IAP therapy on anti-cancer efficacy.


BALB/c mice were inoculated with CT26 murine colorectal cancer cells into the right flank. 5-FU (30 mg/kg) was given IP QD for 5 consecutive days. IAP (0.5 mg/kg) or vehicle was administered PO BID throughout the study. Mice were evaluated for stool consistency, tumor growth and survival. A cohort of mice was sacrificed at day 5 for histopathology analysis.


5-FU administration caused loose stools/diarrhea in all the treated animals, which peaked at day 6 and recovered by day 9. Interestingly, mice that received IAP showed a significantly faster recovery (p < 0.03). As expected, 5-FU slowed tumor progression compared to controls (no 5-FU). Surprisingly, IAP addition significantly improved anti-cancer efficacy. Mice treated with IAP showed diminished tumor growth compared to vehicle (at day 19, 1066 vs 1968 mm3, p < 0.05). Furthermore, IAP administration significantly prolonged animal survival when compared to vehicle-treated animals (p < 0.02). Mechanistically, 5-FU led to goblet cell loss whereas IAP treatment protected the goblet cells.


Oral administration of IAP in mice not only improved some of the side effects associated with 5-FU, such as diarrhea and potentially mucositis, but also enhanced the anti-tumor efficacy of 5-FU leading to significantly prolonged survival. Overall, IAP has the potential to become a new therapeutic agent intended to mitigate cancer-treatment side effects and to enhance the overall anti-tumor response.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Synthetic Biologics.


C. Furlan Freguia: Full / Part-time employment: Synthetic Biologics. M. Kaleko: Full / Part-time employment: Synthetic Biologics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.